Logo_Slider

Logo_Slider

►FROM IDEAS TO COMPANIES

OCTALFA is active and involved in supporting entrepreneurship in France. Its purpose is to promote academic and industrial research in the healthcare sector. Its missions are to identify inventions and expertises that will benefit to patients, coordinate research and feasibility studies prior to the inception of the company, define its strategy, set up the management and fund R&D until the market introduction of products or signing of structuring partnerships.

OCTALFA therefore supports companies until they achieve profitability, are sold or receive backing from an industrial or financial organisation.

► OUR APPROACH

IDENTIFICATION

We identify new projects, assess their
feasibility before implementing the strategy
and the economic model.

VALIDATION

We validate the project with the inventor partners.

FUNDING

We fund companies created with a long-term vision.

MANAGEMENT

We define strategy, then structure,
grow and manage companies created.

► DEVELOPED PROJECTS

  • ORPHELIA Pharma

    SINCE 2015
    ORPHELIA Pharma is a pharmaceutical company dedicated to the development and marketing of pediatric drugs for oncology and CNS diseases.

  • Mathym

    INCEPTED IN 2013
    Nanotechnology company dedicated to the development, manufacturing and commercialization of innovative colloidal solutions

  • OREGA Biotech

    INCEPTED IN 2010
    Biotechnology company dedicated to the research and development of novel antibodies for cancer immunotherapy

  • Alizé Pharma 3

    SINCE 2014
    Biopharmaceutical company developing innovative peptides for the treatment of osteoporosis and certain bone diseases

  • MILLENDO THERAPEUTICS

    Millendo Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for endocrine diseases.

  • ALIZÉ PHARMA

    SINCE 2007
    Clinical-stage biopharmaceutical company developing AZP-531, an analog of unacylated ghrelin for the treatment of Prader-Willi Syndrome and type 2 Diabetes. Acquired mainly by Millendo Therapeutics in 2017.

  • Nightswapping

    SINCE 2014
    Startup company developing novel collaborative tourism tools

  • JUVISE Pharmaceuticals

    FROM 2011 TO 2017
    Pharmaceutical company marketing products to treat psychiatric, inflammatory and respiratory diseases.

► NEWS PROJECTS

  • Pierre Attali joins ORPHELIA Pharma Board Of Directors
  • Meet us at the following congresses in 2018

    Jeremy Bastid will attend the following H1-2018 congresses:

    ANR – Advances in Neuroblastoma Research
    San Francisco May 9 -12

    ASCO – American Society of Clinical Oncology
    Chicago June 1 – 5

    BIO International Convention – Boston June 4 – 7

  • ORPHELIA Pharma announces the filing of a European Marketing Authorization Application for Kigabeq®
  • News from GRAFTYS and Juvisé Pharmaceuticals

    OTONNALE announces the sale of its stake in GRAFTYS, a medtech company involved in orthopedic devices. The purchase of GRAFTYS shares was executed in the last months of 2017 by a Belgian holding set up by Enrico Bastianelli, former CEO of Bone Therapeutics.

    OTONNALE also indicates that Juvisé Pharmaceuticals has fully reimbursed the convertible bonds issued in 2011.

    We wish these two companies a full success in their next development stages.

  • ORPHELIA Pharma strengthens its capital base and accelerates its development
  • Merry Christmas and Happy New year 2018

    initiative OCTALFA wishes you a Merry Christmas and a Happy New Year 2018

  • Millendo Therapeutics acquires Alizé Pharma

    The clinical-stage company focused on novel treatments for endocrine diseases will develop Alizé’s livoletide (AZP-531) for PWS.

  • Mathym launches filyxio®, a radiopacifying nano-dispersion made from ytterbium trifluoride (YbF3)

    Mathym SAS, a company specialized in the development, manufacturing and commercialization of nano-dispersions dedicated to biomedical applications, announces today the complete implementation of its first manufacturing line and the beginning of commercialization of filyxio®.